Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from ZyVersa Therapeutics ( (ZVSA) ).
On February 27, 2026, ZyVersa Therapeutics entered into a Securities Purchase Agreement with accredited investors for a $1 million private placement of convertible promissory notes and accompanying Series A-4 common stock purchase warrants. The notes bear 10% annual interest, mature in 12 months, and are convertible into common stock at a discount to future offering or market prices, subject to a $0.02 per-share floor, while the five-year warrants become exercisable six months after issuance at a premium to a future qualified offering or market-based price.
The deal includes anti-dilution protections, resale registration commitments for the underlying shares within specified timelines, and restrictions on dividends, redemptions, and variable rate transactions while the notes or warrants are outstanding. ZyVersa’s obligations under the notes are guaranteed by its wholly owned subsidiary, and the exempt, non-solicited offering is intended to provide working capital, reinforcing the company’s near-term liquidity while potentially diluting existing shareholders upon conversion or exercise.
The most recent analyst rating on (ZVSA) stock is a Hold with a $0.15 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Neutral.
The score is primarily constrained by very weak financial performance: immaterial revenue, extremely large losses, heavy negative free cash flow, and negative equity. Technicals provide some offset via short-term momentum (price above 20/50/100-day averages with positive MACD), but elevated RSI/Stoch suggests the move is stretched, and valuation remains unattractive due to negative earnings and no indicated dividend yield.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. is a Delaware-based biopharmaceutical company focused on developing therapeutic products, with its common stock traded at a par value of $0.0001 per share. The company operates in the life sciences industry and accesses capital markets through private placements with accredited investors to support its working capital needs.
Average Trading Volume: 77,457
Technical Sentiment Signal: Hold
Current Market Cap: $2.15M
Learn more about ZVSA stock on TipRanks’ Stock Analysis page.